5.6 Neurotransmitters and Neuromodulators: The Chemical Language of Performance

Executive summary. Neurons communicate with two broadly different kinds of chemical signal. Fast transmitters, mainly glutamate and GABA, carry the content of a message point-to-point in under a millisecond. Neuromodulators, mainly dopamine, noradrenaline, serotonin and acetylcholine, are released from small clusters of cells onto very large territories and change how the receiving circuits behave for seconds to minutes. Almost everything an athlete cares about subjectively — drive, focus, readiness, tolerance of discomfort, whether today’s session is remembered tomorrow — is modulator business. This article covers the life cycle of a transmitter, the two receptor families, the five main modulatory systems and, importantly, the limits of what any of this licenses you to conclude about supplements.

‌

Key takeaways

1. Roughly speaking, glutamate is the main excitatory transmitter and GABA the main inhibitory one. Together they account for the great majority of synapses in the brain.
2. Neuromodulators are not simply excitatory or inhibitory. Their effect depends on which receptor subtype they reach, and a single molecule can do opposite things at two receptors.
3. Ionotropic receptors are ion channels and act in under a millisecond. Metabotropic receptors work through second messengers over tens of milliseconds to minutes. This is the single most useful distinction in the chapter.
4. Clearance matters as much as release. Reuptake transporters and degrading enzymes determine how long a signal lasts, which is why most psychoactive drugs target clearance rather than synthesis.
5. Precursor availability is rarely the limiting step for a healthy, adequately fed person. This is the main reason that “eat more of the precursor, get more of the transmitter” reasoning usually fails.
6. Modulator state is part of the training stimulus. The same session performed alert and performed exhausted is not the same session, because the learning rate applied to it differs.

‌

Beginner section: Messages and volume knobs

Two things have to happen for you to move. A message has to get from one neuron to the next, and the receiving neuron has to be in a state where it takes that message seriously. Those are two separate jobs done by two different kinds of chemical.

‌

The messengers are the fast transmitters. Think of them as words. Glutamate says go, GABA says stop, and between them they do most of the actual talking in your brain and spinal cord. They act almost instantly and only across the tiny gap between two specific cells.

‌

The volume knobs are the neuromodulators. Think of them as tone of voice. Dopamine is roughly about pursuit and whether something was better or worse than expected. Noradrenaline is roughly about alertness and urgency. Serotonin is roughly about mood, patience and how willing you are to wait. Acetylcholine is roughly about focus and marking a moment as worth learning from. These come from small clusters of cells that project very widely, so when they fire they change the behaviour of enormous amounts of brain at once.

‌

‌

Two cautions before you go further, because this is the part of neuroscience most often oversold. First, none of these molecules has a single job, and every one-word summary above is a simplification you should be prepared to abandon. Second, the fact that a molecule is involved in a feeling does not mean that swallowing more of its raw ingredient will produce more of the feeling. Synthesis is almost never the bottleneck.

‌

‌

The practical takeaway for a beginner is simple. You do not train transmitters. You train in states, and the state you are in decides how much of a session actually sticks. Sleep, food, stress and session order are the levers that change state. That is the honest version of everything that gets sold as biohacking.

‌

Advanced section: The life cycle, the receptor families, and the five systems

The life cycle of a transmitter, and where it is regulated

Understanding regulation requires following one molecule from raw material to disposal. Every stage below is a genuine control point, and knowing which stage a given intervention acts on is the difference between a mechanistic claim and marketing.

‌

‌

• Synthesis. Amino acid precursors are converted by enzymes, usually with a single rate-limiting step. For dopamine and noradrenaline the limiting enzyme is tyrosine hydroxylase; for serotonin it is tryptophan hydroxylase. Because these enzymes are normally close to saturated with substrate, extra precursor produces much less extra transmitter than intuition suggests (Boulton et al., 1988).
• Vesicular packaging. Transporters such as VMAT2 concentrate monoamines into vesicles using a proton gradient. This is the step amphetamines disrupt, which is why they release transmitter independently of normal firing (Nestler et al., 2015).
• Release. An action potential opens voltage-gated calcium channels at the active zone; calcium entry triggers vesicle fusion. Release is probabilistic per vesicle, which is why firing pattern, not just firing rate, changes the signal (Kandel et al., 2013).
• Receptor binding. The consequence depends entirely on receptor subtype, described below. Presynaptic autoreceptors also exist and provide negative feedback, damping further release.
• Clearance. Reuptake transporters such as DAT, NET and SERT recover transmitter for reuse; enzymes such as monoamine oxidase and catechol-O-methyltransferase break it down. The overwhelming majority of clinically used psychoactive drugs act here (Nestler et al., 2015).

‌

This is why the honest answer to “how do I raise my dopamine?” is that the question is poorly formed. You can transiently increase release, you can slow clearance, you can change receptor sensitivity over weeks, and these have different consequences. Article 5.8 deals with what happens when the last of those is pushed hard.

‌

Ionotropic and metabotropic receptors

This distinction explains more apparent contradictions in the popular literature than any other single fact in neurochemistry.

‌

‌

An ionotropic receptor is itself an ion channel. Glutamate binding to an AMPA receptor lets sodium in and depolarises the cell within a fraction of a millisecond. GABA binding to a GABA-A receptor lets chloride in and hyperpolarises it (Purves et al., 2018). These receptors carry the message. The NMDA receptor is a special case worth knowing, because it requires both glutamate binding and prior depolarisation to open, making it a coincidence detector and the central player in long-term potentiation (Bliss & Collingridge, 1993).

‌

A metabotropic receptor is not a channel. It is coupled to a G protein and triggers an intracellular cascade — cyclic AMP, protein kinase A, phosphorylation of downstream targets. The effect arrives more slowly, lasts longer, and typically changes how the cell responds to other inputs rather than driving it directly. All dopamine receptors are metabotropic, as are most serotonin and adrenergic receptors.

‌

The practical consequence: Dopamine acting on a D1-family receptor and dopamine acting on a D2-family receptor can have opposing effects on the same circuit, because D1 receptors generally couple to stimulatory G proteins and D2 receptors to inhibitory ones. Any sentence beginning “dopamine makes you…” is therefore incomplete without specifying where and on which receptor.

‌

‌

The five systems, briefly, before their own articles

Each of the modulatory systems gets a fuller treatment later in this module. What follows is the orientation you need to read those articles.

‌

• Dopamine. Cell bodies in the ventral tegmental area and substantia nigra. Best characterised computationally as reporting reward prediction error, and behaviourally as supporting the willingness to expend effort (Doya, 2008). Covered in Articles 5.7 and 5.8.
• Noradrenaline. Cell bodies almost entirely in the locus coeruleus. Sets arousal and, in the influential Aston-Jones and Cohen account, controls the trade-off between exploiting the current task and exploring alternatives (Aston-Jones & Cohen, 2005). Relevant to warm-up, competition arousal and overreaching.
• Serotonin. Cell bodies in the raphe nuclei. Involved in mood, aggression regulation, satiety and, in a well-supported computational account, in patience and the willingness to wait for delayed reward (Doya, 2008; Cools et al., 2011).
• Acetylcholine. Two sources: Basal forebrain projections to cortex, and brainstem nuclei. At the neuromuscular junction it is the transmitter of muscle contraction; in the brain it raises signal-to-noise and gates plasticity, effectively marking which moments are worth learning from (Sarter et al., 2005).
• Histamine and the peptides. Histaminergic neurons of the tuberomammillary nucleus support wakefulness. Beyond these, a large set of neuropeptides acts as co-transmitters and is covered in Article 5.12 on hypothalamic peptidergic systems.

‌

‌

The timescale figure above is worth dwelling on, because it is where most confusion about training and supplementation lives. A compound that changes a receptor’s conductance in milliseconds and a training block that changes gene transcription over weeks are not competing explanations for the same phenomenon; they operate in different bands.

‌

‌

‌

Why precursor loading usually disappoints

The reasoning is intuitive: Transmitters are built from amino acids, so eating more of the amino acid should build more transmitter. Three facts get in the way.

‌

1. Enzyme saturation. The rate-limiting enzymes are normally operating near their maximum with respect to substrate. Adding substrate to a saturated enzyme adds little product (Fernstrom & Fernstrom, 2007).
2. Competitive transport. Large neutral amino acids, including tyrosine, tryptophan, leucine, isoleucine, valine and phenylalanine, share the same transporter into the brain. Their brain concentration depends on their ratio to competitors, not on absolute intake, which is why a protein-rich meal can lower brain tryptophan availability despite containing tryptophan (Pardridge, 1998).
3. Autoregulation. Presynaptic autoreceptors and feedback inhibition of synthesis actively resist changes in transmitter availability.

‌

There are documented exceptions, mostly under stress or depletion rather than at baseline: Tyrosine supplementation has shown modest cognitive protection under acute stressors such as cold and sleep deprivation in some trials, which is consistent with catecholamine synthesis becoming substrate-limited only when demand is unusually high (Fernstrom & Fernstrom, 2007). That is a narrow claim and should not be generalised into a daily performance strategy. Article 5.10 goes through the amino acid evidence properly, and Article 5.20 covers supplements.

‌

Nothing in this section is medical advice. If you are considering supplementation, particularly alongside any medication that affects monoamines, discuss it with a qualified clinician rather than reasoning from mechanism alone.

‌

Practical section: What this actually changes about how you train

Neurochemistry rarely changes what exercise you should do. It changes when you should do it, what state you should be in, and how you should interpret a bad session.

‌

• Treat state as a programmable variable. Schedule technically demanding and novel work when arousal and cholinergic focus are highest, which for most people is not at the end of a long working day. Save volume-dominant work for degraded states.
• Protect the consolidation window. The minutes-to-hours band in Figure 4 is when learning is stabilised. Sleep is the single largest lever on it, which is why Article 5.17 is placed where it is.
• Use arousal deliberately, not maximally. Noradrenergic arousal has an inverted-U relationship with performance on complex tasks (Aston-Jones & Cohen, 2005). Maximum activation is right for a maximal deadlift and wrong for a technical skill under time pressure.
• Do not diagnose yourself from a mechanism. “Low dopamine” and “burnt-out receptors” are not measurable in a gym and are not clinical categories. Persistent low mood, anhedonia or loss of drive warrants a conversation with a doctor, not a supplement stack.

‌

A useful discipline when you read a claim about neurochemistry and performance is to ask which stage of Figure 2 it acts on, which receptor family it engages, and which band of Figure 4 it operates in. Claims that cannot answer those three questions are usually not claims about neurochemistry at all.

‌

‌

Sport applications

• Early-morning competition. Arousal systems are still ramping. A longer, more stimulating warm-up is a legitimate intervention rather than a placebo.
• Multi-day tournaments. Accumulated modulatory fatigue shows up as flat affect and poor decisions before it shows up in force output. Track mood and decision quality, not just jump height.
• Skill blocks in team sport. Place them where cholinergic focus is intact. A technical block after a maximal conditioning session mostly consolidates poor movement.
• Weight-class sports. Energy restriction affects modulator systems and mood well before it affects strength. Plan technical work earlier in a cut.
• Endurance events. Serotonergic and noradrenergic changes during very prolonged exercise are part of why pacing decisions deteriorate late. Rehearse decision rules in advance so you are not making them fresh when tired.

‌

Common mistakes

• Treating dopamine as a pleasure chemical. The best-supported account is about prediction error and effort, not enjoyment (Robinson & Berridge, 1993). Getting this wrong leads directly to bad conclusions about motivation.
• Assuming a molecule has one effect. Effect depends on receptor subtype and location. Opposite outcomes from the same molecule are the norm, not an anomaly.
• Loading precursors and expecting a transmitter increase. Enzyme saturation and competitive transport mean this usually does very little in a well-fed person.
• Confusing timescales. A supplement acting over an hour and a training block acting over ten weeks are not rival explanations for the same adaptation.
• Self-diagnosing neurotransmitter deficiency. These states are not measurable outside a research or clinical setting, and persistent symptoms deserve proper assessment.
• Chasing maximal arousal for every session. The relationship with performance is an inverted U, and complex skills peak at lower arousal than maximal strength does.

‌

Coaching cues

• Ask what state a session needs before you ask what exercises it contains.
• Novel and technical first, familiar and heavy second, volume last.
• If your drive is flat for more than a couple of weeks, look at sleep, food intake and life stress before looking at supplements.
• Match warm-up intensity to the arousal the task actually needs.
• Treat sleep as part of the session, because that is where the learning is stabilised.
• When you read a neurochemistry claim, ask which stage, which receptor, which timescale.

‌

FAQs

What is the difference between a neurotransmitter and a neuromodulator?

The distinction is functional rather than absolute, and some molecules do both jobs. A fast transmitter is released into a narrow synapse and acts on one target cell within a millisecond or so, carrying the content of a message. A neuromodulator is released from a diffusely projecting system and acts over seconds to minutes on many cells at once, changing how those cells respond to other inputs. Glutamate and GABA are the archetypal transmitters; dopamine, noradrenaline, serotonin and acetylcholine are the archetypal modulators.

‌

Is glutamate bad for you, given it is in food as monosodium glutamate?

Dietary glutamate and synaptic glutamate are largely separate pools. Glutamate is a very poor crosser of the blood-brain barrier, and brain glutamate is synthesised locally, principally from glutamine supplied by astrocytes (Pardridge, 1998). Concerns about dietary glutamate affecting brain signalling are not well supported.

‌

Can training change my neurotransmitter systems long term?

Regular exercise is associated with changes in monoaminergic function, receptor expression and growth-factor signalling in both animal and human studies, and exercise has a reasonably robust effect on mood in clinical trials. What is not well supported is the ability to predict or measure a specific transmitter change in an individual athlete from a training programme.

‌

Why do stimulants work if precursor loading does not?

Because they act at different stages. Stimulants mainly interfere with clearance and vesicular storage, forcing transmitter into the synapse regardless of firing. Precursor loading acts on synthesis, which is already close to saturated. This is a clear illustration of why the stage of action matters more than the molecule involved.

‌

Does GABA taken as a supplement calm you down?

Orally ingested GABA crosses the blood-brain barrier poorly, and the evidence for meaningful central effects at typical supplement doses is weak and inconsistent. Any effects reported are more plausibly peripheral or expectancy-driven. This is a topic Article 5.20 covers with the trial evidence attached.

‌

Where does acetylcholine fit, given it also makes muscles contract?

Acetylcholine is used in two very different places. At the neuromuscular junction it is the transmitter that triggers muscle fibre contraction through nicotinic receptors. In the brain it is released by basal forebrain and brainstem nuclei and acts largely through muscarinic receptors to raise signal-to-noise and enable plasticity. Same molecule, different receptors, different job.

‌

Recommended videos

Each video below was chosen because it covers a specific part of this article in more depth than text alone allows.

‌

‌

‌

‌

‌

‌

Related reading on FitXplor

• 5.5 The Athlete’s Brain: Functional Neuroanatomy for Performance
• 1.5 The Nervous System and Athletic Performance
• 1.4 Exercise Physiology and Energy Systems
• 1.7 Recovery Science and Adaptation
• 5.1 The Psychology Behind Peak Performance

‌

References

Purves, D., Augustine, G. J., Fitzpatrick, D., et al. (Eds.). (2018). Neuroscience (6th ed.). Oxford University Press.

Kandel, E. R., Schwartz, J. H., Jessell, T. M., Siegelbaum, S. A., & Hudspeth, A. J. (Eds.). (2013). Principles of Neural Science (5th ed.). McGraw-Hill.

Nestler, E. J., Hyman, S. E., Holtzman, D. M., & Malenka, R. C. (2015). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (3rd ed.). McGraw-Hill.

Doya, K. (2008). Modulators of decision making. Nature Neuroscience, 11(4), 410–416.

Aston-Jones, G., & Cohen, J. D. (2005). An integrative theory of locus coeruleus-norepinephrine function. Annual Review of Neuroscience, 28, 403–450.

Sarter, M., Hasselmo, M. E., Bruno, J. P., & Givens, B. (2005). Unravelling the attentional functions of cortical cholinergic inputs. Brain Research Reviews, 48(1), 98–111.

Fernstrom, J. D., & Fernstrom, M. H. (2007). Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. The Journal of Nutrition, 137(6 Suppl 1), 1539S–1547S.

Pardridge, W. M. (1998). Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochemical Research, 23(5), 635–644.

Bliss, T. V. P., & Collingridge, G. L. (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361, 31–39.

Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews, 18(3), 247–291.

Boulton, A. A., Baker, G. B., & Baker, J. M. (Eds.). (1988). Neurotransmitter Enzymes. Humana Press.

Cools, R., Nakamura, K., & Daw, N. D. (2011). Serotonin and dopamine: unifying affective, activational, and decision functions. Neuropsychopharmacology, 36(1), 98–113.